Patent Assignment
Reel/Frame 014520/0982
Change of Name
Recorded: 2004-04-15
Received: 2004-04-15
Pages: 17
Assignor
BIOGEN IDEC MA, INC.
Executed: 2003-12-03
Assignee
BIOGEN IDEC MA INC.
14 CAMBRIDGE CENTER, CAMBRIDGE, MA, 02142, UNITED STATES
Covered Properties
(91)
Surrogate markers of neuropathic pain
Application:
10/784,004 →
Methods for treating or preventing skin disorders using cd2-binding agents
Application:
10/470,764 →
Detecting protein similarity
Application:
60/524,084 →
Structural interactions fingerprint (SIFt)
Application:
60/524,083 →
Molecules and Methods for Inhibiting Shedding of Kim-1
Application:
10/718,321 →
Antibodies and variants thereof that contain altered constant domains
Application:
60/519,744 →
Fc receptor-binding polypeptides, variants with modified glycosylation patterns, and uses therefor
Application:
60/519,746 →
Fc receptor-binding polypeptides, variants obtained by sidechain repacking, and uses therefor
Application:
60/519,734 →
Fc receptor-binding polypeptides with altered effector function and uses therefor
Application:
60/519,747 →
Fc receptor-binding polypeptides, pH-specific variants derived by electrostatic optimization, and uses therefor
Application:
60/519,743 →
Fc receptor-binding polypeptides, variants derived by electrostatic optimization, and uses therefor
Application:
60/519,735 →
Mutants defined by electrostatic modeling within the human Fc domain that can modulate human antibody half-life
Application:
60/519,733 →
Cripto Blocking Antibodies and Uses Thereof
Application:
10/693,538 →
Therapeutic regimens for baff antagonists
Application:
60/512,880 →
FLP-mediated recombination
Application:
60/511,610 →
Antibodies to Vla-1
Application:
10/474,832 →
Cell adhesion inhibitors
Application:
10/679,478 →
Cell Adhesion Inhibitors
Application:
10/677,756 →
Neublastin expression constructs
Application:
60/507,483 →
Treatment using neublastin polypeptides
Application:
10/669,853 →
Ret ligand (RetL) for stimulating neural and renal growth
Application:
10/668,936 →
Kidney Injury-Related Molecules
Application:
10/655,506 →
Adenosine receptor antagonists and methods of making and using the same
Application:
10/646,454 →
Altered antibodies
Application:
60/490,087 →
Cell Adhesion Inhibitors
Application:
10/625,626 →
Aglycosyl anti-CD154 (CD40 Ligand) antibodies and uses thereof
Application:
60/490,186 →
Method for the treatment of fibrosis
Application:
10/625,260 →
Method of Enhancing Delivery of a Therapeutic Nucleic Acid
Application:
10/618,299 →
Structural interactions fingerprint (SIFt)
Application:
60/484,308 →
Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof
Application:
60/478,284 →
Adenosine receptor antagonists and methods of making and using the same
Application:
10/461,534 →
Hbv Capsid-Binding Peptide Immunogens
Application:
10/448,546 →
A1 Adenosine Receptro Antagonists
Application:
10/446,573 →
Treatment for Inflammatory Bowel Disease
Application:
10/428,662 →
Polymer-conjugated, glycosylated neublastin
Application:
60/463,899 →
Humanized Anti-Lt-Beta-R Antibodies
Application:
10/412,406 →
Triazolo(1,5-c)pyrimidines & pyrazolo(1,5-c)pyrimidines and methods of making and using the same
Application:
60/461,355 →
Triazolopyrazines and methods of making and using the same
Application:
60/461,546 →
A2a adenosine receptor antagonists
Application:
60/461,484 →
Triazolo(1,5-a)pyrimidines & pyrazolo(1,5-a) pyrimidines and methods of making and using the same
Application:
60/461,349 →
Triazolotriazines & pyrazolotriazines and methods of making and using the same
Application:
60/461,356 →
GP286 Nucleic Acids and Polypeptides
Application:
10/312,495 →
Truncated soluble BAFF receptor
Application:
60/458,707 →
Renal Regulatory Elements and Methods of Use Thereof
Application:
10/311,388 →
Stable liquid interferon formulations
Application:
10/397,108 →
Methods and Compositions for Therapies Using Genes Encoding Secreted Proteins Such as Interferon-Beta
Application:
10/395,712 →
Cripto Mutant and Uses Thereof
Application:
10/390,566 →
Tweak Receptor Agonists as Anti-Angiogenic Agents
Application:
10/380,611 →
Methods of designing and producing novel compounds having improved binding affinity for CD154 or other trimeric proteins
Application:
10/377,688 →
Method for Identifying Potential Agonists or Antagonists Using Structure Coordinates of the Complex of Extracellular Domain of Human CD154 and the Fab Fragment of Humanized Monoclonal Antibody 5C8
Application:
10/378,567 →
Novel CD40 : CD154 Binding Interruptor Compounds and Use Thereof to Treat Immunological Complications
Application:
10/377,928 →
Gp354 nucleic acids and polypeptides
Application:
10/312,528 →
Polymer Conjugates of Mutated Neublastin
Application:
10/356,264 →
Methods for treating or preventing skin disorders using CD2-binding agents
Application:
10/329,599 →
Cd154 variants
Application:
10/297,452 →
Nucleic Acids Encoding Train-R: a Cysteine Rich Member of the Tnf-Receptor Family
Application:
10/303,502 →
Therapeutic applications of T-BAM (CD40L) technology to treat diseases involving smooth muscle cells
Application:
10/298,508 →
Absolute quantitation of nucleic acids by RT-PCR
Application:
10/294,781 →
Method for Promoting Neovascularization
Application:
10/275,997 →
CD154 blockade therapy for pancreatic islet tissue transplantation
Application:
10/270,783 →
Cell Adhesion Inhibitors
Application:
10/260,340 →
Treatment of immune complex disease with anti-CD40L antibodies
Application:
10/260,639 →
Treatment for Inflammatory Bowel Disease with a Fibronectin Polypeptide
Application:
10/252,978 →
Endothelial cell-leukocyte adhesion molecules (ELAMs) and molecules involved in leukocyte adhesion (MILAs)
Application:
10/234,041 →
Heterologous Polypeptide of the Tnf Family
Application:
10/214,065 →
Polynucleotides encoding members of the human b lymphocyte activation antigen b7 family and polypeptides encoded thereby
Application:
10/069,626 →
Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses
Application:
10/202,740 →
PanCAM nucleic acids and polypeptides
Application:
10/180,410 →
Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
Application:
10/170,841 →
Caip-Like Gene Family
Application:
10/144,621 →
Computational method for inferring elements of gene regulatory network from temporal patterns of gene expression
Application:
10/140,556 →
CD154 blockade therapy for therapeutic protein inhibitor syndrome
Application:
10/127,228 →
Use of a CD40:CD154 binding interruptor to treat immunological complications of the eye
Application:
10/125,264 →
Use of a CD40:CD154 binding interruptor to prevent counter-adaptive immune responses, particularly graft rejection
Application:
10/120,272 →
Therapies for chronic renal failure using one or more integrin antagonists
Application:
10/095,496 →
Methods for Inhibiting Lymphotoxin Beta Receptor Signalling
Application:
10/077,406 →
Methods of Treatment by Administering an Anti-Bcma Antibody
Application:
10/077,438 →
Method of therapeutic administration of anti-CD40L compounds
Application:
10/015,832 →
Method for the Treatment of Inflammatory Disorders
Application:
09/996,738 →
Lymphotoxin-Beta, Lymphotoxin-Beta Complexes, Pharmaceutical Preparations and Therapeutic Uses Thereof
Application:
10/040,281 →
Soluble Lymphotoxin-Beta Receptors as Therapeutic Agents for the Treatment of Systemic Lupus Erythematosus
Application:
10/003,211 →
Anti-Lymphotoxin-Beta Receptor Antibodies as Anti-Tumor Agents
Application:
09/931,402 →
Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
Application:
09/905,810 →
Interferon-Beta-La-Immunoglobulin Fusion Proteins and Uses
Application:
09/832,659 →
Polymer Conjugates of Interferon Beta-1A and Uses
Application:
09/832,658 →
Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
Application:
09/829,031 →
Crystals of the alpha 1 beta 1 integrin I-domain and their use
Application:
09/826,716 →
Common Gamma Chain Blocking Agents
Application:
09/824,286 →
Methods of Treating Multiple Myeloma and Myeloma-Induced Bone Resorption Using Integrin Antagonists
Application:
09/805,840 →
Method of modulating memory effector T-cells and compositions
Application:
09/796,033 →
Active Lymphotoxin-Beta Receptor Immunoglobulin Chimeric Protein Compositions
Application:
09/767,370 →